Fig. 4
Combination therapy with OATD-02 and anti-PD-1 enhances antitumor immunity and prolongs survival in CT26 tumor-bearing mice. (A) Experimental design: CT26 tumor-bearing mice (n = 18) were treated with OATD-02 (100 mg/kg, PO, BID) from day 1 until the end of the study. Anti-PD-1 antibodies (2.5 mg/kg, IP) were administered on days 6, 10, 14, and 18. On day 15, a subset of animals (n = 6) was sacrificed for flow cytometry analysis, while the remaining mice (n = 12) were monitored for survival. (B) Kaplan–Meier survival curves comparing treatment groups (Vehicle, Anti-PD-1, OATD-02, and combination therapy). Log-rank test significance: *p < 0.05. (C) Flow cytometry analysis of immune cell populations in tumors, lymph nodes, and spleens on day 15. Effector CD4⁺ and CD8⁺ T cells were identified as CD44⁺CD62L⁻ (within CD4⁺ or CD8⁺ populations, respectively). In panel C, “Combined” refers to animals treated with a combination of anti-PD-1 and OATD-02. Statistical analysis: Kruskal–Wallis test followed by Dunn’s post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
